

Number 663 • January 2017

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Quinapril/HCTZ 20 mg/12.5 mg Tablet (DIN 02408775) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **February 13, 2017**.

QUINAPRIL / HYDROCHLOROTHIAZIDE

20 MG / 12.5 MG TABLET					
00002408775	APO-QUINAPRIL / HCTZ	ΑΡΧ	\$ 0.6865		
00002237368	ACCURETIC 20 / 12.5	PFI	\$ 0.9468		

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Quinapril/HCTZ 20 mg/25 mg Tablet (DIN 02408783) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **February 13, 2017**.

QUINAPRIL / HYDROCHLOROTHIAZIDE

20 MG / 25 MG TABLET					
00002408783	APO-QUINAPRIL / HCTZ	ΑΡΧ	\$ 0.6512		
00002237369	ACCURETIC 20 / 25	PFI	\$ 0.9067		

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Quinapril/HCTZ 10 mg/12.5 mg Tablet (DIN 02408767) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **February 16, 2017**.

QUINAPRIL / HYDROCHLOROTHIAZIDE

10 MG / 12.5 MG TABLET					
00002408767	APO-QUINAPRIL / HCTZ	ΑΡΧ	\$ 0.6865		
00002237367	ACCURETIC 10 / 12.5	PFI	\$ 0.9468		

... continued from previous page

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Mometasone 0.1% Topical Cream (DIN 02367157) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **February 17, 2017**.

MOMETASONE FUROATE

0.1% TOPICAL CREAM

00002367157	TARO-MOMETASONE	TAR	\$ 0.5708
00000851744	ELOCOM	MFC	\$ 0.7098

Temporary benefit added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Teva-Spironolactone 100 mg Tablet (DIN 00613223) manufactured by Teva Canada Limited, Aldactone 100 mg Tablet (DIN 00285455) manufactured by Pfizer Canada Inc. will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of January 11, 2017, all claims for Aldactone 100 mg Tablet (DIN 00285455) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at https://www.ab.bluecross.ca/providers/pharmacy-home.html.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit https://www.ab.bluecross.ca/providers/pharmacy-home.php**



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.663 2017/01

